364 related articles for article (PubMed ID: 38607041)
21. Gene signature developed for predicting early relapse and survival in early-stage pancreatic cancer.
Huang L; Yuan X; Zhao L; Han Q; Yan H; Yuan J; Guan S; Xu X; Dai G; Wang J; Shi Y
BJS Open; 2023 May; 7(3):. PubMed ID: 37196196
[TBL] [Abstract][Full Text] [Related]
22. New Treatment Options in Metastatic Pancreatic Cancer.
Fudalej M; Kwaśniewska D; Nurzyński P; Badowska-Kozakiewicz A; Mękal D; Czerw A; Sygit K; Deptała A
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190255
[TBL] [Abstract][Full Text] [Related]
23.
Zhang Z; Zhang H; Liao X; Tsai HI
Front Cell Dev Biol; 2023; 11():1147676. PubMed ID: 37152291
[TBL] [Abstract][Full Text] [Related]
24. Multiple Strategies to Develop Small Molecular KRAS Directly Bound Inhibitors.
Zhou X; Ji Y; Zhou J
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110848
[TBL] [Abstract][Full Text] [Related]
25. Feedback activation of EGFR/wild-type RAS signaling axis limits KRAS
Feng J; Hu Z; Xia X; Liu X; Lian Z; Wang H; Wang L; Wang C; Zhang X; Pang X
Oncogene; 2023 May; 42(20):1620-1633. PubMed ID: 37020035
[TBL] [Abstract][Full Text] [Related]
26. Claudin-4: A New Molecular Target for Epithelial Cancer Therapy.
Fujiwara-Tani R; Mori S; Ogata R; Sasaki R; Ikemoto A; Kishi S; Kondoh M; Kuniyasu H
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982569
[TBL] [Abstract][Full Text] [Related]
27. Advances in Liquid Biopsy Technology and Implications for Pancreatic Cancer.
Raufi AG; May MS; Hadfield MJ; Seyhan AA; El-Deiry WS
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835649
[TBL] [Abstract][Full Text] [Related]
28. Construction and validation of an aging-related gene signature predicting the prognosis of pancreatic cancer.
Wang D; Zhang Y; Wang X; Zhang L; Xu S
Front Genet; 2023; 14():1022265. PubMed ID: 36741321
[No Abstract] [Full Text] [Related]
29. Sotorasib in
Strickler JH; Satake H; George TJ; Yaeger R; Hollebecque A; Garrido-Laguna I; Schuler M; Burns TF; Coveler AL; Falchook GS; Vincent M; Sunakawa Y; Dahan L; Bajor D; Rha SY; Lemech C; Juric D; Rehn M; Ngarmchamnanrith G; Jafarinasabian P; Tran Q; Hong DS
N Engl J Med; 2023 Jan; 388(1):33-43. PubMed ID: 36546651
[TBL] [Abstract][Full Text] [Related]
30. BRAF-Driven Pancreatic Cancer: Prevalence, Molecular Features, and Therapeutic Opportunities.
Ciner AT; Jiang Y; Hausner P
Mol Cancer Res; 2023 Apr; 21(4):293-300. PubMed ID: 36534729
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer.
Kemp SB; Cheng N; Markosyan N; Sor R; Kim IK; Hallin J; Shoush J; Quinones L; Brown NV; Bassett JB; Joshi N; Yuan S; Smith M; Vostrejs WP; Perez-Vale KZ; Kahn B; Mo F; Donahue TR; Radu CG; Clendenin C; Christensen JG; Vonderheide RH; Stanger BZ
Cancer Discov; 2023 Feb; 13(2):298-311. PubMed ID: 36472553
[TBL] [Abstract][Full Text] [Related]
32. Glimmers of hope for targeting oncogenic KRAS-G12D.
Tang D; Kang R
Cancer Gene Ther; 2023 Mar; 30(3):391-393. PubMed ID: 36414681
[TBL] [Abstract][Full Text] [Related]
33. The Renaissance of CDK Inhibitors in Breast Cancer Therapy: An Update on Clinical Trials and Therapy Resistance.
Abdelmalak M; Singh R; Anwer M; Ivanchenko P; Randhawa A; Ahmed M; Ashton AW; Du Y; Jiao X; Pestell R
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358806
[TBL] [Abstract][Full Text] [Related]
34. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer.
Goodwin CM; Waters AM; Klomp JE; Javaid S; Bryant KL; Stalnecker CA; Drizyte-Miller K; Papke B; Yang R; Amparo AM; Ozkan-Dagliyan I; Baldelli E; Calvert V; Pierobon M; Sorrentino JA; Beelen AP; Bublitz N; Lüthen M; Wood KC; Petricoin EF; Sers C; McRee AJ; Cox AD; Der CJ
Cancer Res; 2023 Jan; 83(1):141-157. PubMed ID: 36346366
[TBL] [Abstract][Full Text] [Related]
35. Niraparib-induced STAT3 inhibition increases its antitumor effects.
Zhao Q; Kohut A; Li YJ; Martincuks A; Austria T; Zhang C; Santiago NL; Borrero RM; Phan XT; Melstrom L; Rodriguez-Rodriguez L; Yu H
Front Oncol; 2022; 12():966492. PubMed ID: 36324587
[TBL] [Abstract][Full Text] [Related]
36. Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma.
Ng CF; Glaspy J; Placencio-Hickok VR; Thomassian S; Gong J; Osipov A; Hendifar AE; Moshayedi N
J Natl Compr Canc Netw; 2022 Oct; 20(10):1076-1079. PubMed ID: 36240849
[TBL] [Abstract][Full Text] [Related]
37. Anti-tumor efficacy of a potent and selective non-covalent KRAS
Hallin J; Bowcut V; Calinisan A; Briere DM; Hargis L; Engstrom LD; Laguer J; Medwid J; Vanderpool D; Lifset E; Trinh D; Hoffman N; Wang X; David Lawson J; Gunn RJ; Smith CR; Thomas NC; Martinson M; Bergstrom A; Sullivan F; Bouhana K; Winski S; He L; Fernandez-Banet J; Pavlicek A; Haling JR; Rahbaek L; Marx MA; Olson P; Christensen JG
Nat Med; 2022 Oct; 28(10):2171-2182. PubMed ID: 36216931
[TBL] [Abstract][Full Text] [Related]
38. Using All Our Genomes: Blood-based Liquid Biopsies for the Early Detection of Cancer.
Adams E; Sepich-Poore GD; Miller-Montgomery S; Knight R
View (Beijing); 2022 Jan; 3(1):. PubMed ID: 35872970
[TBL] [Abstract][Full Text] [Related]
39. The discovery of a non-competitive GOT1 inhibitor, hydralazine hydrochloride, via a coupling reaction-based high-throughput screening assay.
Wu Q; Sun Z; Chen Z; Liu J; Ding H; Luo C; Wang M; Du D
Bioorg Med Chem Lett; 2022 Oct; 73():128883. PubMed ID: 35820623
[TBL] [Abstract][Full Text] [Related]
40. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial.
Reiss KA; Mick R; Teitelbaum U; O'Hara M; Schneider C; Massa R; Karasic T; Tondon R; Onyiah C; Gosselin MK; Donze A; Domchek SM; Vonderheide RH
Lancet Oncol; 2022 Aug; 23(8):1009-1020. PubMed ID: 35810751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
